PIK-93 is the first reported PI4-kinase inhibitor, which is able to inhibit PI4KIIIbeta at low-nanomolar range (IC50=19 nM). In addition, this compound is a potent inhibitor of PI3Kgamma in vitro (IC50=16 nM). This compound inhibits p110alpha, p110beta, p110delta with IC50s of 0.039, 0.59, 0.12 µM respectively. PIK-93 hydrogen bonds to the backbone amide and carbonyl of Val882 and between its sulphonamide and Asp964. PI4KIIIbeta is esential for replication of numerous viruses P. falciparum. Inhibition of plasmodial PI4KIIIbeta has been proposed as an anti-malaria treatment.
